Union Bancaire Privee UBP SA bought a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 660 shares of the company’s stock, valued at approximately $42,000.
A number of other hedge funds also recently modified their holdings of the stock. US Bancorp DE lifted its position in iShares U.S. Pharmaceuticals ETF by 137.0% during the third quarter. US Bancorp DE now owns 384 shares of the company’s stock worth $27,000 after purchasing an additional 222 shares during the period. Assetmark Inc. lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 100.0% during the 3rd quarter. Assetmark Inc. now owns 432 shares of the company’s stock worth $31,000 after acquiring an additional 216 shares during the period. Allworth Financial LP boosted its position in shares of iShares U.S. Pharmaceuticals ETF by 9.4% during the 3rd quarter. Allworth Financial LP now owns 1,853 shares of the company’s stock worth $131,000 after acquiring an additional 159 shares in the last quarter. EP Wealth Advisors LLC bought a new position in iShares U.S. Pharmaceuticals ETF in the third quarter valued at approximately $157,000. Finally, Farther Finance Advisors LLC increased its stake in iShares U.S. Pharmaceuticals ETF by 97.1% in the third quarter. Farther Finance Advisors LLC now owns 2,482 shares of the company’s stock valued at $175,000 after acquiring an additional 1,223 shares during the last quarter.
iShares U.S. Pharmaceuticals ETF Price Performance
NYSEARCA IHE opened at $72.85 on Wednesday. The business has a fifty day moving average price of $68.02 and a two-hundred day moving average price of $69.33. The stock has a market capitalization of $735.79 million, a PE ratio of 6.49 and a beta of 0.58. iShares U.S. Pharmaceuticals ETF has a fifty-two week low of $62.67 and a fifty-two week high of $72.94.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Read More
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- How to Use Stock Screeners to Find Stocks
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- How to Calculate Stock Profit
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- The How and Why of Investing in Gold Stocks
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.